Amgen, Inc. (AMGN) SVP Cynthia M. Patton Sells 1,777 Shares of Stock

Amgen, Inc. (NASDAQ:AMGN) SVP Cynthia M. Patton sold 1,777 shares of the firm’s stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total value of $360,517.76. Following the completion of the sale, the senior vice president now directly owns 23,090 shares of the company’s stock, valued at approximately $4,684,499.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

AMGN opened at $202.93 on Tuesday. The company has a quick ratio of 2.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.05. The firm has a market capitalization of $132.70 billion, a price-to-earnings ratio of 15.00, a PEG ratio of 2.16 and a beta of 1.41. Amgen, Inc. has a 12-month low of $163.31 and a 12-month high of $210.19.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.45 by $0.24. The business had revenue of $5.90 billion during the quarter, compared to the consensus estimate of $5.78 billion. Amgen had a return on equity of 54.14% and a net margin of 9.44%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.27 earnings per share. On average, equities analysts predict that Amgen, Inc. will post 14.24 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 7th. Shareholders of record on Friday, November 16th will be issued a $1.32 dividend. The ex-dividend date is Thursday, November 15th. This represents a $5.28 dividend on an annualized basis and a yield of 2.60%. Amgen’s dividend payout ratio (DPR) is 41.97%.

Institutional investors and hedge funds have recently bought and sold shares of the business. Capital International Investors increased its holdings in shares of Amgen by 301.4% during the third quarter. Capital International Investors now owns 11,093,182 shares of the medical research company’s stock valued at $2,299,506,000 after acquiring an additional 8,329,861 shares in the last quarter. Capital World Investors bought a new position in shares of Amgen during the third quarter valued at $952,900,000. FMR LLC increased its holdings in shares of Amgen by 4.4% during the third quarter. FMR LLC now owns 35,823,268 shares of the medical research company’s stock valued at $7,425,805,000 after acquiring an additional 1,505,266 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Amgen by 36.2% during the third quarter. AQR Capital Management LLC now owns 2,907,575 shares of the medical research company’s stock valued at $602,711,000 after acquiring an additional 773,506 shares in the last quarter. Finally, Beutel Goodman & Co Ltd. bought a new position in shares of Amgen during the second quarter valued at $86,723,000. Institutional investors and hedge funds own 76.94% of the company’s stock.

AMGN has been the subject of a number of research analyst reports. Cann reaffirmed a “buy” rating and issued a $224.00 price target on shares of Amgen in a research note on Monday, October 1st. Royal Bank of Canada reaffirmed a “neutral” rating and issued a $193.00 price target on shares of Amgen in a research note on Monday, September 10th. Oppenheimer reaffirmed a “buy” rating and issued a $224.00 price target on shares of Amgen in a research note on Tuesday, August 28th. Goldman Sachs Group reaffirmed a “buy” rating and issued a $229.00 price target on shares of Amgen in a research note on Friday, October 12th. Finally, Jefferies Financial Group set a $220.00 price target on Amgen and gave the stock a “buy” rating in a research note on Monday, October 8th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $204.55.

WARNING: “Amgen, Inc. (AMGN) SVP Cynthia M. Patton Sells 1,777 Shares of Stock” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.com-unik.info/2018/12/04/amgen-inc-amgn-svp-cynthia-m-patton-sells-1777-shares-of-stock.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Featured Story: Market Capitalization and Individual Investors

Insider Buying and Selling by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit